VNQ vs XBI
Vanguard Real Estate ETF vs SPDR S&P Biotech ETF
- • VNQ has the lower expense ratio at 0.13% vs 0.35% for XBI.
- • VNQ pays a higher dividend yield (3.63%).
Side-by-side metrics
| Metric | VNQ | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.13% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.63% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $69.46B | $10.92B |
YTD return | 13.11% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.92 | 1.01 |
P/E ratio | 30.62 | — |
Last price | $96.76 | $156.41 |
Inception | — | — |
Issuer | Vanguard | State Street |
VNQ top holdings
| VRTPX | Vanguard Real Estate II Index | 14.51% |
| WELL | Welltower Inc | 9.12% |
| PLD | Prologis Inc | 6.86% |
| EQIX | Equinix Inc | 5.65% |
| AMT | American Tower Corp | 4.32% |
| SPG | Simon Property Group Inc | 3.69% |
| DLR | Digital Realty Trust Inc | 3.68% |
| O | Realty Income Corp | 2.85% |
| PSA | Public Storage | 2.69% |
| VMRK | Vivmark Residential | 2.46% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About VNQ
VNQ (Vanguard Real Estate ETF) is US REITs and real-estate operating companies. Managed by Vanguard, the fund carries $69.5B in assets under management, an expense ratio of 0.13%, a dividend yield of 3.63%. Its largest holding is Vanguard Real Estate II Index (VRTPX), which represents 14.5% of the portfolio. Real Estate is the fund's largest sector exposure at 99.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.